Back to Search Start Over

Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples

Authors :
Dell'Aquila, Marco
Tralongo, Pietro
Granitto, Alessia
Martini, Maurizio
Capodimonti, Sara
Curatolo, Mariangela
Fiorentino, Vincenzo
Pontecorvi, Alfredo
Fadda, Guido
Lombardi, Celestino Pio
Raffaelli, Maco
Pantanowitz, Liron
Larocca, Luigi Maria
Rossi, Esther
Martini, Maurizio (ORCID:0000-0002-6260-6310)
Pontecorvi, Alfredo (ORCID:0000-0003-0570-6865)
Fadda, Guido (ORCID:0000-0003-2013-7293)
Lombardi, Celestino Pio (ORCID:0000-0001-8910-6693)
Larocca, Luigi Maria (ORCID:0000-0003-1739-4758)
Rossi, Esther (ORCID:0000-0003-3819-4229)
Dell'Aquila, Marco
Tralongo, Pietro
Granitto, Alessia
Martini, Maurizio
Capodimonti, Sara
Curatolo, Mariangela
Fiorentino, Vincenzo
Pontecorvi, Alfredo
Fadda, Guido
Lombardi, Celestino Pio
Raffaelli, Maco
Pantanowitz, Liron
Larocca, Luigi Maria
Rossi, Esther
Martini, Maurizio (ORCID:0000-0002-6260-6310)
Pontecorvi, Alfredo (ORCID:0000-0003-0570-6865)
Fadda, Guido (ORCID:0000-0003-2013-7293)
Lombardi, Celestino Pio (ORCID:0000-0001-8910-6693)
Larocca, Luigi Maria (ORCID:0000-0003-1739-4758)
Rossi, Esther (ORCID:0000-0003-3819-4229)
Publication Year :
2022

Abstract

Aims: Several papers have shown that programmed death-ligand 1 (PD-L1) expression is a relevant predictive biomarker in anti-PD-L1 cancer immunotherapy. While its role in several human cancers is correlated with poor prognosis and resistance to anticancer therapies, in thyroid cancers the role of PD-L1 remains questionable. Few articles have studied PD-L1 in thyroid fine-needle aspiration cytology (FNAC), demonstrating a possible correlation with papillary thyroid carcinoma. However, its role in oncocytic thyroid lesions remains controversial. We accordingly examine the performance of PD-L1 immunostaining in liquid based cytology (LBC) from oncocytic lesions. Methods: From January 2019 to March 2021, 114 thyroid lesions diagnosed by FNAC from lesions with a predominant oncocytic component, were enrolled for evaluation by PD-L1 immunostaining on both LBC and corresponding histology samples. Results: The FNAC cohort included 51 benign (B, negative controls), 4 atypia of undetermined significance/follicular lesions of undetermined significance (AUS/FLUS), 57 follicular lesions (follicular neoplasm/suspicious for FN, FN/SFN) and 2 suspicious for malignancy (SFM) cases. Fifty-four cases (11B, 2 AUS/FLUS, 39 FN/SFN and 2 SFM) had histological follow-up including: 1B case resulted as a hyperplastic oxyphilic nodule in Hashimoto thyroiditis (HT), 10B as goitre, 2 AUS/FLUS cases as oncocytic adenomas (OAs); 39 FN/SFN included 27 OAs, 4 FA and 8 oncocytic follicular carcinoma (OFC). The two SFM cases were diagnosed on histopathology as OAs. Increased plasma membrane and cytoplasmic PD-L1 expression were found in 47 cases of the LBC cases (41.2%). Among the histological series, 67.3% of OAs and 75% of OFC had PD-L1 expression, while negative PD-L1 was found in hyperplastic oncocytic cells in HT. A positivity in more than 30% of the neoplastic cells was found in 72.9% of the cases including six OFC. Conclusions: These data suggest that PD-L1 expression is expressed in oncocytic

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1372911144
Document Type :
Electronic Resource